̽»¨¾«Ñ¡

The concept of inhibiting blood vessel growth in tumors has been successfully translated into clinical practice. Today, many anti-angiogenic drugs are routinely used to treat various cancers. Despite this clinical success, survival benefits in humans are generally limited and many clinical needs are unanswered. Most cancer patients die as a result of metastases, but the underlying mechanisms are not fully understood, but involve complex interactions between different cell types and signaling molecules. It is crucial to try to understand these interactions in order to be able to develop effective drugs for the treatment of metastases. Our project aims to improve the therapeutic effect of anti-angiogenic drugs, selection of patients predicted to respond to treatment, bypass drug resistance and achieve long-term treatment

which are important issues in clinical practice. The project also aims to understand the mechanisms behind metastases and identify new goals for treatment. The information generated in this project can be directly used to improve the effect of anti-angiogenic drugs for the treatment of cancer. We believe that our results will lead to significant conceptual progress and improve both survival and quality of life for millions of patients. In this project, we plan to further explore new pathways towards the understanding of many clinically unsolved issues related to tumor angiogenesis and antiangiogenesis treatment. We have received exciting preclinical results and have proposed a new concept to explain the positive mechanisms behind combination therapy. If our preclinical results can be interpreted successfully for clinical practice, we believe that millions of cancer patients will benefit from our studies.

The concept of inhibiting blood vessel growth in tumors has been successfully translated into clinical practice. Today, many anti-angiogenic drugs are routinely used to treat various cancers. Despite this clinical success, survival benefits in humans are generally limited and many clinical needs are unanswered. Most cancer patients die as a result of metastases, but the underlying mechanisms are not fully understood, but involve complex interactions between different cell types and signaling molecules. It is crucial to try to understand these interactions in order to be able to develop effective drugs for the treatment of metastases. Our project aims to improve the therapeutic effect of anti-angiogenic drugs, selection of patients predicted to respond to treatment, bypass drug resistance and achieve long-term treatment

which are important issues in clinical practice. The project also aims to understand the mechanisms behind metastases and identify new goals for treatment. The information generated in this project can be directly used to improve the effect of anti-angiogenic drugs for the treatment of cancer. We believe that our results will lead to significant conceptual progress and improve both survival and quality of life for millions of patients. In this project, we plan to further explore new pathways towards the understanding of many clinically unsolved issues related to tumor angiogenesis and antiangiogenesis treatment. We have received exciting preclinical results and have proposed a new concept to explain the positive mechanisms behind combination therapy. If our preclinical results can be interpreted successfully for clinical practice, we believe that millions of cancer patients will benefit from our studies.

Tumors cannot grow without blood supply and the proliferation of tumor cells often occurs through blood and lymph vessels. This concept was already proposed 43 years ago and several medications have been developed for treatment by targeting blood vessels in tumors. Unfortunately, the clinical effects of these drugs in humans have been relatively modest, and patients have developed resistance. It has been seen that these drugs also affect the blood vessels in healthy tissues and organs, which has led to undesirable side effects. The project aims to understand the underlying mechanisms of angiogenesis in cancer in order to improve the therapeutic outcomes. The project focuses on investigating mechanisms for tumor angiogenesis in the growth of tumors, spreading and how they respond to treatment. We have identified several interesting factors and molecules that regulate angiogenesis in tumors and we plan to further study their role in the microenvironment in tumors. We expect our studies in these complex mechanisms to lead to the development of more and more effective drugs for the treatment of cancer patients. We aim to improve both survival and quality of life for millions of patients. In this project, we plan to further explore new pathways towards the understanding of many clinically unsolved issues related to tumor angiogenesis and antiangiogenesis treatment. We have received exciting preclinical results and have proposed a new concept to explain the positive mechanisms behind combination therapy. If our preclinical results can be interpreted successfully for clinical practice, we believe that millions of cancer patients will benefit from our studies.

Tumors cannot grow without blood supply and the proliferation of tumor cells often occurs through blood and lymph vessels. This concept was already proposed 43 years ago and several medications have been developed for treatment by targeting blood vessels in tumors. Unfortunately, the clinical effects of these drugs in humans have been relatively modest, and patients have developed resistance. It has been seen that these drugs also affect the blood vessels in healthy tissues and organs, which has led to undesirable side effects. The project aims to understand the underlying mechanisms of angiogenesis in cancer in order to improve the therapeutic outcomes. The project focuses on investigating mechanisms for tumor angiogenesis in the growth of tumors, spreading and how they respond to treatment. We have identified several interesting factors and molecules that regulate angiogenesis in tumors and we plan to further study their role in the microenvironment in tumors. We expect our studies in these complex mechanisms to lead to the development of more and more effective drugs for the treatment of cancer patients. We aim to improve both survival and quality of life for millions of patients. In this project, we plan to further explore new pathways towards the understanding of many clinically unsolved issues related to tumor angiogenesis and antiangiogenesis treatment. We have received exciting preclinical results and have proposed a new concept to explain the positive mechanisms behind combination therapy. If our preclinical results can be interpreted successfully for clinical practice, we believe that millions of cancer patients will benefit from our studies.

Tumors cannot grow without blood supply and the proliferation of tumor cells often occurs through blood and lymph vessels. This concept was already proposed 43 years ago and several medications have been developed for treatment by targeting blood vessels in tumors. Unfortunately, the clinical effects of these drugs in humans have been relatively modest, and patients have developed resistance. It has been seen that these drugs also affect the blood vessels in healthy tissues and organs, which has led to undesirable side effects. The project aims to understand the underlying mechanisms of angiogenesis in cancer in order to improve the therapeutic outcomes. The project focuses on investigating mechanisms for tumor angiogenesis in the growth of tumors, spreading and how they respond to treatment. We have identified several interesting factors and molecules that regulate angiogenesis in tumors and we plan to further study their role in the microenvironment in tumors. We expect our studies in these complex mechanisms to lead to the development of more and more effective drugs for the treatment of cancer patients. We aim to improve both survival and quality of life for millions of patients. In this project, we plan to further explore new pathways towards the understanding of many clinically unsolved issues related to tumor angiogenesis and antiangiogenesis treatment. We have received exciting preclinical results and have proposed a new concept to explain the positive mechanisms behind combination therapy. If our preclinical results can be interpreted successfully for clinical practice, we believe that millions of cancer patients will benefit from our studies.